JAK2 and glioblastoma: Indeed, Stechishin et al. found that targeted JAK2/STAT3 inhibition in orthotopic GBM xenografts regardless of molecular strategy led to increased cytotoxicity of GSCs regardless of MGMT promoter methylation status [157].